Skip to content

Author

Kulranjan Singh

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients.

BACKGROUND/AIMS MicroRNA-429 (miR-429), a member of the miR-200 family, has been implicated in epithelial-mesenchymal transition and tumor progression, yet its clinicopathological significance in breast cancer remains unclear. This study aimed to evaluate serum miR-429 expression in treatment-naïve breast cancer patien...

Shivangini Sharma, Taniya Suryavanshi, Preeti Agarwal et al. · 0 citations
Aug 2026

Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage.

Globally, Triple-Negative Breast Cancer (TNBC) has huge unmet medical need as it has limited targeted therapeutic options. However, it has well-known therapeutic vulnerabilities for selective inhibition of pathways like EGFR, m-TOR, PARP, EZH2, PD1-PDL1 etc. Analysis of publicly available databases clearly suggest that...

Saumya Ranjan Satrusal, Arpita Banerjee, Arpon Biswas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.